The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effectiveness of a nurse-led, screening-triggered, early specialized palliative care intervention program for patients with advanced lung cancer: A multicenter randomized controlled trial.
 
Yoshihisa Matsumoto
No Relationships to Disclose
 
Ayumi Okizaki
No Relationships to Disclose
 
Daisuke Kiuchi
No Relationships to Disclose
 
Shigeki Umemura
No Relationships to Disclose
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - CAC Croit Corporation; Japan Tobacco Inc; Kowa; Ono Pharmaceutical
Speakers' Bureau - Asahi Kasei; Daiichi Sankyo; Nipro Corporation; Takeda; Tsumura & Co.
Research Funding - 3H Clinical Trial; 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice; Eisai; Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka; Puravida Technologies (Inst); Senju Pharmaceutical; Welby (Inst)
 
Shunsuke Oyamada
No Relationships to Disclose
 
Daisuke Fujisawa
Honoraria - Eisai; Hisamitsu Pharmaceutical; Novo Nordisk; Pfizer
Research Funding - Eisai
 
Naoko Kobayashi
No Relationships to Disclose
 
Tempei Miyaji
Honoraria - AYUMI; Merck; Pfizer; Takeda
Research Funding - 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); CAC Croit Corporation (Inst); FMD K&L Japan (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Luminary Medical (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); New Age Trading (Inst); Nipro Corporation (Inst); NOBORI Ltd. (Inst); Ono Pharmaceutical (Inst); Puravida Technologies (Inst); Welby (Inst)
 
Tomoe Mashiko
Employment - Suxac
 
Eriko Satomi
Honoraria - Bayer (I); Boehringer Ingelheim (I); Boston Scientific (I); Bristol-Myers Squibb (I); Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo (I); Eisai; Eisai (I); Fukuda Denshi (I); Hisamitsu Pharmaceutical; Johnson & Johnson (I); Medtronic (I); Mundipharma; Pfizer (I); Shionogi; St. Jude Medical (I); TERUMO; TOA EIYO (I); Tsumura & Co.
Consulting or Advisory Role - Japan Lifeline (I)
Research Funding - Biotronik International (I)
 
Yuko Uehara
No Relationships to Disclose
 
Kazuhiro Kosugi
No Relationships to Disclose
 
Hiroya Kinoshita
No Relationships to Disclose
 
Masanori Mori
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Shionogi; Takeda
 
Tatsuya Yoshida
Speakers' Bureau - Archer; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai/Roche; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; MSD K.K.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Lilly Japan (Inst); LOXO (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yosuke Uchitomi
No Relationships to Disclose
 
Tatsuya Morita
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Mundipharma; Ono Yakuhin; Shionogi; Takeda